Article Text

Download PDFPDF

CS-31 Safety of hydroxychloroquine withdrawal in older adults with systemic lupus erythematosus
  1. Peter Izmirly1,
  2. Nicole Bornkamp1,
  3. Anna Zezon1,
  4. Chung-E Tseng1,
  5. H Michael Belmont1,
  6. Anca Askanase2,
  7. Jane E Salmon3,
  8. Michael D Lockshin3 and
  9. Jill P Buyon1
  1. 1New York University School of Medicine, USA
  2. 2Columbia University College of Physicians and Surgeons, USA
  3. 3Hospital for Special Surgery, USA


Background Although hydroxychloroquine (HCQ) is a mainstay of treatment for patients with Systemic Lupus Erythematosus (SLE), ocular toxicity can result from accumulated exposure. The introduction of highly sensitive tools has engendered even more concern. As the longevity of patients with SLE improves, additional data will help physicians accurately balance the risk of ocular toxicity and the risk of disease flare, especially in older patients who have stable/quiescent disease. Accordingly, this study was initiated to examine the safety of HCQ withdrawal in older SLE patients.

Methods Data were obtained by retrospective chart review at three lupus centers. Twenty-seven patients met the following inclusion criteria:≥4 ACR criteria, disease duration ≥5 years, HCQ use of 200–400 mg per day ≥5 years, and discontinuation of hydroxychloroquine at ≥age 55 years. The comparator group comprised 39 age, gender and racial/ethnic matched patients who remained on HCQ. The primary outcome was a clinically meaningful flare within one year of HCQ withdrawal, defined as moderate or severe, using a revised version of the SELENA-SLEDAI Flare composite that separates mild from moderate flares, evaluates each organ system separately, and incorporates increases in corticosteroid dose and/or addition of immunosuppressive agents. Mild flares were considered secondary outcomes.

Results Demographics are provided in table 1. There was a trend toward longer disease duration in the HCQ withdrawal group but no difference in prevalence of prior lupus nephritis between the groups. The reasons for HCQ withdrawal were maculopathy (n=13), presumed/biopsy proven cardiomyopathy (n=2), patient request (n=4), and miscellaneous other reasons (n=8). There was no difference in the primary or secondary outcomes between the groups (table 1). Two patients had a moderate flare after discontinuing HCQ, of whom one had arthritis treated with methotrexate and one had thrombocytopenia (>30K) and proteinuria of 2 grams/d (baseline 700 mg). Three patients had severe flares while continuing HCQ, of whom two were hospitalized, one for seizures and one for pericarditis; the third had worsening nephritis (urinary protein >4 g/d, requiring treatment). Two patients had moderate flares while remaining on HCQ, one of whom had a rash and arthritis treated with tofacitinib and one a rash treated with prednisone.

Conclusions In this retrospective study of older patients with SLE on long-term HCQ, withdrawal did not increase the risk of moderate or severe flares. These data provide reassurance regarding the safety of withdrawing HCQ in stable older SLE patients.

Abstract CS-31 Table 1

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.